High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy
- 1 January 2005
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 44 (12) , 1267-1278
- https://doi.org/10.2165/00003088-200544120-00005
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected SubjectsAntimicrobial Agents and Chemotherapy, 2003
- Factors Affecting the Clinical Development of Cytochrome P450 3A SubstratesClinical Pharmacokinetics, 2003
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Therapeutic Drug MonitoringDrugs, 2003
- High Concentrations of Nelfinavir as an Independent Risk Factor for Lipodystrophy in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2002
- Interactions among Drugs for HIV and Opportunistic InfectionsNew England Journal of Medicine, 2001
- Factors Affecting Adherence to Antiretroviral TherapyClinical Infectious Diseases, 2000
- NelfinavirDrugs, 2000
- Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitorsAIDS, 2000
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999